沙库巴曲缬沙坦钠对左室射血分数≤40%的慢性心力衰竭患者的影响

Effects of Sacubitril and Valsartan Sodium in Chronic Heart Failure Patients with Left Ventricular Ejection Fraction≤40%

目的探讨沙库巴曲缬沙坦钠对左室射血分数(LVEF)≤40%的慢性心力衰竭(CHF)患者的影响。方法选取2019年1月至2020年7月襄城县人民医院接收的98例LVEF≤40%的CHF患者作为研究对象,依据治疗方案分为常规治疗组(49例)和联合治疗组(49例)。常规治疗组接受常规治疗,联合治疗组在常规治疗组的基础上加用沙库巴曲缬沙坦钠治疗,比较两组临床疗效、主要心血管不良事件(MACE)发生率、治疗前及治疗1、3个月的心功能、实验室指标。结果联合治疗组总有效率较常规治疗组高(P>0.05);治疗1、3个月,联合治疗组LVEF高于常规治疗组,左室舒张末期内径小于常规治疗组,血清亲环素A、生化分化因子-15水平低于常规治疗组(P<0.05);两组MACE发生率对比,差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦钠治疗LVEF≤40%的CHF患者,可提高临床效果,改善心功能,调节血清亲环素A、生化分化因子-15水平。

Objective To discuss the effects of sacubitril and valsartan sodium in patients with chronic heart failure(CHF)with left ventricular ejection fraction(LVEF)≤40%.Methods A total of 98 patients with CHF and LVEF≤40%from January 2019 to July 2020 in Xiangcheng County People’s Hospital were selected and divided into routine treatment group(49 cases)and combined treatment group(49 cases)according to drug treatment schemes.The routine treatment group received routine symptomatic support treatment,and the combined treatment group received sacubitril and valsartan sodium based on the routine treatment group.The clinical efficacy,major adverse cardiovascular events(MACE)incidence,cardiac function,laboratory indicators before treatment and after 1 month and 3 months of treatment were compared between two groups.Results The total effective rate of combined treatment group was higher than that of routine treatment group(P>0.05).After 1 month and 3 months of treatment,the LVEF of combined treatment group was higher than that of routine treatment group,the left ventricular end-diastolic diameter was lower than that of routine treatment group,and the serum levels of cyclophilin A and growth differentiation factor-15 of combined treatment group were lower than those of routine treatment group(P<0.05).There was no statistical difference in the incidence of MACE between the two groups(P>0.05).Conclusion Sacubitril and valsartan sodium can improve clinical efficacy of CHF patients with LVEF≤40%,improve cardiac function and regulate serum levels of cyclophilin A and growth differentiation factor-15.